Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis[1] Approximately 22 million women in US have osteopenia, ...

EAST HANOVER, N.J., April 11 New data show that aonce-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg wassignificantly better than risedronate at increasing bone mass in patients ...

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Sept. 1, 2011 — The FDA warns that the osteoporosis drug Reclast (zoledronic acid) raises the risk of kidney failure. The warning is targeted at patients who already suffer from kidney impairment.